shown activity against different strains of Plasmodium falciparum. Seventeen new derivatives were prepared and tested in vitro for their activities against blood stages of two strains of Plasmodium falciparum. Several structure–activity relationships were revealed. The activity strongly depended on the nature of the acyl moiety. Only benzamides showed promising activity. The substitution pattern of their
一项针对疟疾的药物风险投资(MMV)项目的N-酰化
呋喃3胺已显示出对不同菌株恶性疟原虫的活性。制备了17种新的衍
生物,并在体外测试了它们对两株恶性疟原虫血液阶段的活性。揭示了几种构效关系。活性强烈取决于酰基部分的性质。仅苯甲酰胺显示出有希望的活性。它们的苯环的取代方式影响化合物的活性和细胞毒性。另外,通过P
AMPA计算(log P,log D,
配体效率)或通过实验确定其物理
化学参数(渗透率)。该ñ-(4-(3,4-
二乙氧基苯基)-1,2,5-恶二唑-3-基)-3-(三
氟甲基)苯甲酰胺具有良好的理化性质,对
氯喹敏感菌株具有很高的抗血浆活性(IC 50( NF54)= 0.019 µM)甚至更高的抗多重耐药菌株的抗疟原虫活性(IC 50(K 1)= 0.007 µM)。与MMV化合物相比,提高了通透性和抗多抗性菌株的活性。